Title,Authors,Platform,Cited_url,Cited_count,Year
Reversible tumorigenesis by MYC in hematopoietic lineages,"DW Felsher, JM Bishop","Molecular cell 4 (2), 199-207",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2184043546352643908,898,1999
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma,"AP Weng, JM Millholland, Y Yashiro-Ohtani, ML Arcangeli, A Lau, C Wai, ...","Genes & development 20 (15), 2096-2109",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18438844961667036475,815,2006
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer,"CM Shachaf, AM Kopelman, C Arvanitis, Å Karlsson, S Beer, S Mandl, ...","Nature 431 (7012), 1112",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11628854933120463785,780,2004
Sustained loss of a neoplastic phenotype by brief inactivation of MYC,"M Jain, C Arvanitis, K Chu, W Dewey, E Leonhardt, M Trinh, CD Sundberg, ...","Science 297 (5578), 102-104",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5873032309122665544,692,2002
MYC as a regulator of ribosome biogenesis and protein synthesis,"J Van Riggelen, A Yetil, DW Felsher","Nature Reviews Cancer 10 (4), 301",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7737660527174426859,542,2010
Supramolecular stacking of doxorubicin on carbon nanotubes for in vivo cancer therapy,"Z Liu, AC Fan, K Rakhra, S Sherlock, A Goodwin, X Chen, Q Yang, ...","Angewandte Chemie International Edition 48 (41), 7668-7672","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8319205406132375826,15829022045716899991",468,2009
Transient excess of MYC activity can elicit genomic instability and tumorigenesis,"DW Felsher, JM Bishop","Proceedings of the National Academy of Sciences 96 (7), 3940-3944",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11847986832586590060,459,1999
HIF-dependent antitumorigenic effect of antioxidants in vivo,"P Gao, H Zhang, R Dinavahi, F Li, Y Xiang, V Raman, ZM Bhujwalla, ...","Cancer cell 12 (3), 230-238",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2997044063195168559,448,2007
MYC regulates the antitumor immune response through CD47 and PD-L1,"SC Casey, L Tong, Y Li, R Do, S Walz, KN Fitzgerald, AM Gouw, V Baylot, ...","Science 352 (6282), 227-231",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15502060667265073364,366,2016
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation,"CH Wu, J Van Riggelen, A Yetil, AC Fan, P Bachireddy, DW Felsher","Proceedings of the National Academy of Sciences 104 (32), 13028-13033",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15010223098624930419,345,2007
MYC activation is a hallmark of cancer initiation and maintenance,"M Gabay, Y Li, DW Felsher","Cold Spring Harbor perspectives in medicine 4 (6), a014241",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18170160477024547312,312,2014
c-Myc is a critical target for C/EBPα in granulopoiesis,"LM Johansen, A Iwama, TA Lodie, K Sasaki, DW Felsher, TR Golub, ...","Molecular and cellular biology 21 (11), 3789-3806",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10336738392692085504,271,2001
CD4+ T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation,"K Rakhra, P Bachireddy, T Zabuawala, R Zeiser, L Xu, A Kopelman, ...","Cancer cell 18 (5), 485-498",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4651070978590366741,269,2010
Atomic accuracy in predicting and designing noncanonical RNA structure,"R Das, J Karanicolas, D Baker","Nature methods 7 (4), 291",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9083650943919074128,266,2010
Cancer revoked: oncogenes as therapeutic targets,DW Felsher,"Nature Reviews Cancer 3 (5), 375",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2421327449917972911,261,2003
Flavivirus NS1 structures reveal surfaces for associations with membranes and the immune system,"DL Akey, WC Brown, S Dutta, J Konwerski, J Jose, TJ Jurkiw, ...","Science 343 (6173), 881-885",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10713691026525418213,200,2014
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis,"Y Xiang, ZE Stine, J Xia, Y Lu, RS O’Connor, BJ Altman, AL Hsieh, ...","The Journal of clinical investigation 125 (6), 2293-2306",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9871913784157300212,193,2015
Bioorthogonal cyclization-mediated ,"D Ye, AJ Shuhendler, L Cui, L Tong, SS Tee, G Tikhomirov, DW Felsher, ...","Nature chemistry 6 (6), 519",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3601790067841346154,191,2014
NAFLD causes selective CD4,"C Ma, AH Kesarwala, T Eggert, J Medina-Echeverz, DE Kleiner, P Jin, ...","Nature 531 (7593), 253",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4895507734916070196,186,2016
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice,"M Traykova-Brauch, K Schönig, O Greiner, T Miloud, A Jauch, M Bode, ...","Nature medicine 14 (9), 979",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14315522719503881481,179,2008
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead,"WH Goodson III, L Lowe, DO Carpenter, M Gilbertson, A Manaf Ali, ...","Carcinogenesis 36 (Suppl_1), S254-S296","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17162994394602675464,10985950170396655541",166,2015
Suppression of p53 by Notch in lymphomagenesis: implications for initiation and regression,"LJ Beverly, DW Felsher, AJ Capobianco","Cancer research 65 (16), 7159-7168",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2084293256927573788,166,2005
Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts,"DW Felsher, A Zetterberg, J Zhu, T Tlsty, JM Bishop","Proceedings of the National Academy of Sciences 97 (19), 10544-10548",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10990776967769884797,155,2000
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch,"S Giuriato, S Ryeom, AC Fan, P Bachireddy, RC Lynch, MJ Rioth, ...","Proceedings of the National Academy of Sciences 103 (44), 16266-16271",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17200229295087167277,154,2006
Designing a broad-spectrum integrative approach for cancer prevention and treatment,"KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...","Seminars in cancer biology 35, S276-S304",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5894369331567932764,145,2015
Conditional transgenic models define how MYC initiates and maintains tumorigenesis,"C Arvanitis, DW Felsher","Seminars in cancer biology 16 (4), 313-317",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4108707288444609854,144,2006
Developmental context determines latency of MYC-induced tumorigenesis,"S Beer, A Zetterberg, RA Ihrie, RA McTaggart, Q Yang, N Bradon, ...","PLoS biology 2 (11), e332",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2512438536176400883,143,2004
Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression,"A Karlsson, D Deb-Basu, A Cherry, S Turner, J Ford, DW Felsher","Proceedings of the National Academy of Sciences 100 (17), 9974-9979",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6867512040649569536,138,2003
Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations,"Å Karlsson, S Giuriato, F Tang, J Fung-Weier, G Levan, DW Felsher","Blood 101 (7), 2797-2803",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11466496789084415589,137,2003
CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis,"B Das, SS Kashino, I Pulu, D Kalita, V Swami, H Yeger, DW Felsher, ...","Science translational medicine 5 (170), 170ra13-170ra13",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=795124469831361848,126,2013
Cancer prevention and therapy through the modulation of the tumor microenvironment,"SC Casey, A Amedei, K Aquilano, AS Azmi, F Benencia, D Bhakta, ...","Seminars in cancer biology 35, S199-S223",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15509244896336027268,123,2015
"MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase","Z Cao, H Fan-Minogue, DI Bellovin, A Yevtodiyenko, J Arzeno, Q Yang, ...","Cancer research 71 (6), 2286-2297",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16933541091631111415,123,2011
"MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state","Y Li, PS Choi, SC Casey, DL Dill, DW Felsher","Cancer cell 26 (2), 262-272",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17367693403651308176,118,2014
Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance,"Z Cao, BS Ding, P Guo, SB Lee, JM Butler, SC Casey, M Simons, W Tam, ...","Cancer cell 25 (3), 350-365",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=32227273099522773,118,2014
Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens,"AC Fan, D Deb-Basu, MW Orban, JR Gotlib, Y Natkunam, R O'neill, ...","Nature medicine 15 (5), 566",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8771395979940665309,113,2009
MYC disrupts the circadian clock and metabolism in cancer cells,"BJ Altman, AL Hsieh, A Sengupta, SY Krishnanaiah, ZE Stine, ZE Walton, ...","Cell metabolism 22 (6), 1009-1019",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10034582885437420845,112,2015
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma,"T Kapanadze, J Gamrekelashvili, C Ma, C Chan, F Zhao, S Hewitt, ...","Journal of hepatology 59 (5), 1007-1013",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17217445357875480597,103,2013
Basal exon skipping and genetic pleiotropy: A predictive model of disease pathogenesis,"TG Drivas, AP Wojno, BA Tucker, EM Stone, J Bennett","Science translational medicine 7 (291), 291ra97-291ra97","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7016720079890849632,17084961076622223376",102,2015
Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?,DW Felsher,"Cancer research 68 (9), 3081-3086",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3000979459649489383,102,2008
MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species,"S Ray, KR Atkuri, D Deb-Basu, AS Adler, HY Chang, LA Herzenberg, ...","Cancer research 66 (13), 6598-6605",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16410458425877321197,102,2006
Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas,"E Dejean, MH Renalier, M Foisseau, X Agirre, N Joseph, GR De Paiva, ...","Leukemia 25 (12), 1882",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2203378039961311483,101,2011
MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism,"EH Shroff, LS Eberlin, VM Dang, AM Gouw, M Gabay, SJ Adam, ...","Proceedings of the National Academy of Sciences 112 (21), 6539-6544",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=714603523023660413,97,2015
MYC inactivation elicits oncogene addiction through both tumor cell–intrinsic and host-dependent mechanisms,DW Felsher,"Genes & cancer 1 (6), 597-604",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1921380843493914846,95,2010
The interaction between Myc and Miz1 is required to antagonize TGFβ-dependent autocrine signaling during lymphoma formation and maintenance,"J Van Riggelen, J Müller, T Otto, V Beuger, A Yetil, PS Choi, C Kosan, ...","Genes & development 24 (12), 1281-1294",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9473660262471791146,93,2010
SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas,"KY Jang, SJ Noh, N Lehwald, GZ Tao, DI Bellovin, HS Park, WS Moon, ...","PloS one 7 (9), e45119",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7981032702354230486,91,2012
Development of Novel Tumor‐Targeted Theranostic Nanoparticles Activated by Membrane‐Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy,"C Ansari, GA Tikhomirov, SH Hong, RA Falconer, PM Loadman, JH Gill, ...","Small 10 (3), 566-575",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10817522521664937039,89,2014
Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy,"CM Shachaf, DW Felsher","Cancer research 65 (11), 4471-4474",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11868747831570900069,88,2005
Reversibility of oncogene-induced cancer,DW Felsher,"Current opinion in genetics & development 14 (1), 37-42",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11539261000530222399,86,2004
The human BCL6 transgene promotes the development of lymphomas in the mouse,"BW Baron, J Anastasi, A Montag, D Huo, RM Baron, T Karrison, ...","Proceedings of the National Academy of Sciences 101 (39), 14198-14203",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10607390592774122171,84,2004
Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis,"PT Tran, EH Shroff, TF Burns, S Thiyagarajan, ST Das, T Zabuawala, ...","PLoS genetics 8 (5), e1002650",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12111642411003308760,83,2012
Hypoxia in models of lung cancer: implications for targeted therapeutics,"EE Graves, M Vilalta, IK Cecic, JT Erler, PT Tran, D Felsher, L Sayles, ...","Clinical Cancer Research 16 (19), 4843-4852",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15670646776634804525,80,2010
Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance,"CM Shachaf, AJ Gentles, S Elchuri, D Sahoo, Y Soen, O Sharpe, ...","Cancer research 68 (13), 5132-5142",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15882576462959636614,79,2008
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas,"PT Tran, AC Fan, PK Bendapudi, S Koh, K Komatsubara, J Chen, ...","PloS one 3 (5), e2125",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14820319091736696285,77,2008
Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis,"CH Wu, D Sahoo, C Arvanitis, N Bradon, DL Dill, DW Felsher","PLoS genetics 4 (6), e1000090",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8917345779776218204,76,2008
Alteration of the lipid profile in lymphomas induced by MYC overexpression,"LS Eberlin, M Gabay, AC Fan, AM Gouw, RJ Tibshirani, DW Felsher, ...","Proceedings of the National Academy of Sciences 111 (29), 10450-10455",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6760733769460485625,73,2014
The neuronal expression of MYC causes a neurodegenerative phenotype in a novel transgenic mouse,"H Lee, G Casadesus, A Nunomura, X Zhu, RJ Castellani, SL Richardson, ...","The American journal of pathology 174 (3), 891-897",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9963345748714574221,65,2009
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia,"N Omidvar, S Kogan, S Beurlet, C le Pogam, A Janin, R West, ...","Cancer Research 67 (24), 11657-11667",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8122589723340528433,65,2007
Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer,"S Giuriato, K Rabin, AC Fan, CM Shachaf, DW Felsher","Seminars in cancer biology 14 (1), 3-11",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2619276156931694238,65,2004
The effect of environmental chemicals on the tumor microenvironment,"SC Casey, M Vaccari, F Al-Mulla, R Al-Temaimi, A Amedei, ...","Carcinogenesis 36 (Suppl_1), S160-S183",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17587896510186298613,62,2015
p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production,"I Goldstein, K Yizhak, S Madar, N Goldfinger, E Ruppin, V Rotter","Cancer & metabolism 1 (1), 9",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5617268942152212725,62,2013
Development of a micro-computed tomography–based image-guided conformal radiotherapy system for small animals,"H Zhou, M Rodriguez, F Van den Haak, G Nelson, R Jogani, J Xu, X Zhu, ...","International Journal of Radiation Oncology* Biology* Physics 78 (1), 297-305",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8950367314433172798,62,2010
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910. Na,"M Seetharam, AC Fan, M Tran, L Xu, JP Renschler, DW Felsher, ...","Leukemia research 36 (1), 98-103",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2233972817267506409,60,2012
High throughput automated chromatin immunoprecipitation as a platform for drug screening and antibody validation,"AR Wu, TLA Kawahara, NA Rapicavoli, J Van Riggelen, EH Shroff, L Xu, ...","Lab on a Chip 12 (12), 2190-2198",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7586535418395641475,58,2012
Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis,"R Opavsky, SY Tsai, M Guimond, A Arora, J Opavska, B Becknell, ...","Proceedings of the National Academy of Sciences 104 (39), 15400-15405",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18311659459009931353,57,2007
STK38 is a critical upstream regulator of MYC’s oncogenic activity in human B-cell lymphoma,"BC Bisikirska, SJ Adam, MJ Alvarez, P Rajbhandari, R Cox, C Lefebvre, ...","Oncogene 32 (45), 5283",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6298688282955016418,56,2013
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis,"CM Shachaf, OD Perez, S Youssef, AC Fan, S Elchuri, MJ Goldstein, ...","Blood 110 (7), 2674-2684",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16872396969259469507,55,2007
Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis,"RA Hlady, S Novakova, J Opavska, D Klinkebiel, SL Peters, J Bies, ...","The Journal of clinical investigation 122 (1), 163-177",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6077918255962204770,53,2012
Lethal cutaneous disease in transgenic mice conditionally expressing type I human T cell leukemia virus Tax,"H Kwon, L Ogle, B Benitez, J Bohuslav, M Montano, DW Felsher, ...","Journal of Biological Chemistry 280 (42), 35713-35722",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=663730812236387169,53,2005
Conditionally MYC: insights from novel transgenic models,"C Arvanitis, DW Felsher","Cancer letters 226 (2), 95-99",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3780102889657424585,52,2005
Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage–response thresholds,"KM Kampa, JD Acoba, D Chen, J Gay, H Lee, K Beemer, E Padiernos, ...","Proceedings of the National Academy of Sciences 106 (11), 4390-4395",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2969867278909832020,51,2009
Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice,"S Beer, DI Bellovin, JS Lee, K Komatsubara, LS Wang, H Koh, K Börner, ...","Molecular Therapy 18 (1), 161-170",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17395987369830942140,50,2010
CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells,"R Opavsky, SH Wang, P Trikha, A Raval, Y Huang, YZ Wu, B Rodriguez, ...","PLoS genetics 3 (9), e167",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15031788449404232411,50,2007
HIF‐2α Suppresses p53 to Enhance the Stemness and Regenerative Potential of Human Embryonic Stem Cells,"B Das, R Bayat‐Mokhtari, M Tsui, S Lotfi, R Tsuchida, DW Felsher, ...","Stem cells 30 (8), 1685-1695",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14666936333338974202,47,2012
PET imaging of tumor neovascularization in a transgenic mouse model with a novel 64Cu-DOTA-knottin peptide,"CH Nielsen, RH Kimura, N Withofs, PT Tran, Z Miao, JR Cochran, ...","Cancer research 70 (22), 9022-9030",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7276526947099662382,47,2010
Tumor dormancy and oncogene addiction,DW Felsher,"Apmis 116 (7‐8), 629-637",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10190919230277024691,46,2008
Metabolic changes in cancer cells upon suppression of MYC,"E Anso, AR Mullen, DW Felsher, JM Matés, RJ DeBerardinis, NS Chandel","Cancer & metabolism 1 (1), 7",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15589923704716086839,44,2013
Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis,"S Beer, K Komatsubara, DI Bellovin, M Kurobe, K Sylvester, DW Felsher","PloS one 3 (6), e2493",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4734288679104487630,44,2008
Noninvasive molecular imaging of c-Myc activation in living mice,"H Fan-Minogue, Z Cao, R Paulmurugan, CT Chan, TF Massoud, ...","Proceedings of the National Academy of Sciences 107 (36), 15892-15897",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11521045579265939249,41,2010
Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure,"H Lee, Q Chen, JA Wolfram, SL Richardson, A Liner, SL Siedlak, X Zhu, ...","PLoS One 4 (9), e7172",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10662403753560381740,41,2009
How cancers escape their oncogene habit,"S Giuriato, DW Felsher","Cell cycle 2 (4), 328-331",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2840954199899258772,39,2003
Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction,"P Bachireddy, K Rakhra, DW Felsher","Clinical & Experimental Immunology 167 (2), 188-194",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14539690988806206980,37,2012
Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction,"PS Choi, J Van Riggelen, AJ Gentles, P Bachireddy, K Rakhra, SJ Adam, ...","Proceedings of the National Academy of Sciences 108 (42), 17432-17437",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2087909829296388207,37,2011
Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer,"W Lin, N Rajbhandari, C Liu, K Sakamoto, Q Zhang, AA Triplett, SK Batra, ...","Cancer research 73 (6), 1821-1830",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4229229202135227976,36,2013
"Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs","DI Bellovin, B Das, DW Felsher","Systems Biology of Tumor Dormancy, 91-107",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10107445421109035400,36,2013
Survival and death signals can predict tumor response to therapy after oncogene inactivation,"PT Tran, PK Bendapudi, HJ Lin, P Choi, S Koh, J Chen, G Horng, ...","Science translational medicine 3 (103), 103ra99-103ra99",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11554894489041641503,36,2011
Getting at MYC through RAS,"P Bachireddy, PK Bendapudi, DW Felsher","Clinical cancer research 11 (12), 4278-4281",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14355359692311578773,36,2005
"“Picolog,” a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo","BA DeChristopher, AC Fan, DW Felsher, PA Wender","Oncotarget 3 (1), 58",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5549538779852008720,35,2012
Enhanced NFATc1 nuclear occupancy causes T cell activation independent of CD28 costimulation,"M Pan, MM Winslow, L Chen, A Kuo, D Felsher, GR Crabtree","The Journal of Immunology 178 (7), 4315-4321",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7498846471443385871,33,2007
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells,"S Beurlet, N Omidvar, P Gorombei, P Krief, C Le Pogam, N Setterblad, ...","Blood 122 (16), 2864-2876",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2288304883808699012,32,2013
Inactivation of MYC reverses tumorigenesis,"Y Li, SC Casey, DW Felsher","Journal of internal medicine 276 (1), 52-60",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=830294209507557146,31,2014
SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF,"Z Levashova, MV Backer, G Horng, D Felsher, JM Backer, ...","Bioconjugate chemistry 20 (4), 742-749",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7022985996695992463,31,2009
Rehabilitation of cancer through oncogene inactivation,"CM Shachaf, DW Felsher","Trends in molecular medicine 11 (7), 316-321",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1517939454594569674,31,2005
Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells,"CH Contag, R Sikorski, RS Negrin, T Schmidt, AC Fan, P Bachireddy, ...","Cancer research 70 (23), 9837-9845",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8159548636132109415,30,2010
The E47 transcription factor negatively regulates CD5 expression during thymocyte development,"Y Yang, CH Contag, D Felsher, CM Shachaf, Y Cao, LA Herzenberg, ...","Proceedings of the National Academy of Sciences 101 (11), 3898-3902",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4822396212070173749,29,2004
Characterization of MYC-induced tumorigenesis by in situ lipid profiling,"RH Perry, DI Bellovin, EH Shroff, AI Ismail, T Zabuawala, DW Felsher, ...","Analytical chemistry 85 (9), 4259-4262",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3967636074098266864,28,2013
Myc and a Cdk2 senescence switch,"J Van Riggelen, DW Felsher","Nature cell biology 12 (1), 7",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17391226789260412345,28,2010
Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia,"S Giuriato, M Foisseau, E Dejean, DW Felsher, T Al Saati, C Demur, ...","Blood 115 (20), 4061-4070",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7260114382077442804,27,2010
Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy,"S Giuriato, N Faumont, E Bousquet, M Foisseau, A Bibonne, M Moreau, ...","Cancer biology & therapy 6 (8), 1324-1329",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7458980047013944836,27,2007
Tumor dormancy: death and resurrection of cancer as seen through transgenic mouse models,DW Felsher,"Cell cycle 5 (16), 1808-1811",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17465745109562280910,27,2006
"Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma","AM Gouw, LS Eberlin, K Margulis, DK Sullivan, GG Toal, L Tong, RN Zare, ...","Proceedings of the National Academy of Sciences 114 (17), 4300-4305",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17872054191355679304,26,2017
"Reversing cancer from inside and out: oncogene addiction, cellular senescence, and the angiogenic switch",DW Felsher,"Lymphatic research and biology 6 (3-4), 149-154",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4624795621816101796,25,2008
"KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study","RT Swords, PL Greenberg, AH Wei, S Durrant, AS Advani, MS Hertzberg, ...","Leukemia research 50, 123-131","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7774041751279307696,18035526676574140751",24,2016
"MYC Can Enforce Cell Cycle Transit from G1 to S and G2 to S, But not Mitotic Cellular Division, Independent of p27 Inhibition of Cyclin E/CDK2","D Deb-Basu, Å Karlsson, Q Li, CV Dang, DW Felsher","Cell Cycle 5 (12), 1348-1355",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3695199441287676672,24,2006
Pharmacological inactivation of MYC for the treatment of cancer.,"DW Felsher, N Bradon","Drug news & perspectives 16 (6), 370-374",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11825593380227875751,22,2003
Independent rearrangement of Igλ genes in tissue culture-derived murine B cell lines,"DW Felsher, DT Ando, J Braun","International immunology 3 (7), 711-718",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4130269501109210138,22,1991
The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma,"H Miess, B Dankworth, AM Gouw, M Rosenfeldt, W Schmitz, M Jiang, ...","Oncogene 37 (40), 5435",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=490878708810113840,21,2018
 activation cooperates with ,"ST Bailey, AM Smith, J Kardos, SE Wobker, HL Wilson, B Krishnan, ...","Nature communications 8, 15770",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5761430282770132518,20,2017
MYC: master regulator of immune privilege,"SC Casey, V Baylot, DW Felsher","Trends in immunology 38 (4), 298-305",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1303409122075735525,20,2017
A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide,"H Fan-Minogue, S Bodapati, D Solow-Cordero, A Fan, R Paulmurugan, ...","Molecular cancer therapeutics 12 (9), 1896-1905",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=468861120182126216,20,2013
Impact of hydrodynamic injection and phiC31 integrase on tumor latency in a mouse model of MYC-induced hepatocellular carcinoma,"LE Woodard, A Keravala, WE Jung, OL Wapinski, Q Yang, DW Felsher, ...","PLoS One 5 (6), e11367",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10955022716290464160,20,2010
CDK2 is required by MYC to induce apoptosis,"D Deb-Basu, E Aleem, P Kaldis, DW Felsher","Cell Cycle 5 (12), 1342-1347",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14008862159759345540,20,2006
A murine model for B-cell lymphomagenesis in immunocompromised hosts: natural killer cells are an important component of host resistance to premalignant B-cell lines,"DW Felsher, SH Rhim, J Braun","Cancer research 50 (21), 7050-7056",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16879598662789370874,20,1990
Reactive oxygen species regulate nucleostemin oligomerization and protein degradation,"M Huang, P Whang, JV Chodaparambil, DA Pollyea, B Kusler, L Xu, ...","Journal of Biological Chemistry 286 (13), 11035-11046",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16568063492337717453,19,2011
Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC),"R Dhanasekaran, M Gabay-Ryan, V Baylot, I Lai, A Mosley, X Huang, ...","Oncotarget 9 (5), 5517",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11113960237468372324,17,2018
Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down‐modulation,"JT Ney, T Schmidt, C Kurts, Q Zhou, D Eckert, DW Felsher, H Schorle, ...","Hepatology 49 (2), 471-481",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2878271198616227343,17,2009
Oncogene withdrawal engages the immune system to induce sustained cancer regression,"SC Casey, Y Li, AC Fan, DW Felsher","Journal for immunotherapy of cancer 2 (1), 24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5378528300096777059,16,2014
Role of MYCN in retinoblastoma,DW Felsher,"The Lancet Oncology 14 (4), 270-271",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5959255152559574919,16,2013
18F and 18FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation,"C Arvanitis, PK Bendapudi, JR Tseng, SS Gambhir, DW Felsher","Cancer biology & therapy 7 (12), 1947-1951",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10189118823738880336,15,2008
The MYC oncogene is a global regulator of the immune response,"SC Casey, V Baylot, DW Felsher","Blood 131 (18), 2007-2015",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=16008725425412765088,14,2018
p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia,"A Yetil, B Anchang, AM Gouw, SJ Adam, T Zabuawala, R Parameswaran, ...","Oncotarget 6 (6), 3563",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=293240977186416924,14,2015
Activation of Cre recombinase alone can induce complete tumor regression,"Y Li, PS Choi, SC Casey, DW Felsher","PLoS One 9 (9), e107589",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3451164917459331851,14,2014
A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype,"DW Felsher, KA Denis, D Weiss, DT Ando, J Braun","Cancer research 50 (21), 7042-7049",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11315534869171206153,14,1990
Discovery and validation of cancer biomarkers using a protein analysis methodology to analyze specimens,"DW Felsher, A Fan","US Patent App. 10/145,851",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9894721560197427270,13,2018
An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation,"SC Casey, Y Li, DW Felsher","Immunologic research 58 (2-3), 282-291",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10595751128867642747,13,2014
Functional interactions between retinoblastoma and c-MYC in a mouse model of hepatocellular carcinoma,"LA Saddic, S Wirt, H Vogel, DW Felsher, J Sage","PLoS One 6 (5), e19758",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14104129077316919651,13,2011
The Shc-binding site of the βc subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis,"HS Ramshaw, MA Guthridge, FC Stomski, EF Barry, L Ooms, CA Mitchell, ...","Blood 110 (10), 3582-3590","https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6391634990621837054,755754455403823504",13,2007
Stabilization of the Max homodimer with a small molecule attenuates Myc-driven transcription,"NB Struntz, A Chen, A Deutzmann, RM Wilson, E Stefan, HL Evans, ...","Cell chemical biology 26 (5), 711-723. e14",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6133651204534008411,12,2019
Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance,"PS Choi, Y Li, DW Felsher","Proceedings of the National Academy of Sciences 111 (32), E3316-E3324",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2394820758667858329,12,2014
A quantitative PCR method to detect blood microRNAs associated with tumorigenesis in transgenic mice,"AC Fan, MM Goldrick, J Ho, Y Liang, P Bachireddy, DW Felsher","Molecular cancer 7 (1), 74",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=465390611187125701,12,2008
Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model,"S Sander, L Bullinger, A Karlsson, S Giuriato, T Hernandez-Boussard, ...","Oncogene 24 (40), 6101",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17245354739925742151,12,2005
Metabolic vulnerabilities of MYC-induced cancer,"AM Gouw, GG Toal, DW Felsher","Oncotarget 7 (21), 29879",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14910154646371708795,11,2016
BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia,"Y Li, A Deutzmann, PS Choi, AC Fan, DW Felsher","Oncotarget 7 (19), 26926",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6050168346372539061,11,2016
Cancer Therapy: Development of Novel Tumor‐Targeted Theranostic Nanoparticles Activated by Membrane‐Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance …,"C Ansari, GA Tikhomirov, SH Hong, RA Falconer, PM Loadman, JH Gill, ...","Small 10 (3), 417-417",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1573351473723651428,11,2014
DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt’s lymphoma,"CJ Poole, W Zheng, A Lodh, A Yevtodiyenko, D Liefwalker, H Li, ...","Oncotarget 8 (44), 76898",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5329212529405923604,9,2017
Noncanonical roles of the immune system in eliciting oncogene addiction,"SC Casey, DI Bellovin, DW Felsher","Current opinion in immunology 25 (2), 246-258",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9110650809115691064,9,2013
Oncogenes as therapeutic targets.,DW Felsher,"Seminars in cancer biology 14 (1), 1",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13379089481583290141,9,2004
"Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression","JPO Hebb, AR Mosley, F Vences-Catalán, N Rajasekaran, A Rosén, ...","Cancer Immunology, Immunotherapy 67 (1), 47-60",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17377575096183856266,8,2018
TGFβ-dependent gene expression shows that senescence correlates with abortive differentiation along several lineages in Myc-induced lymphomas,"J Müller, B Samans, J Van Riggelen, G Fagà, R Peh KN, CL Wei, H Müller, ...","Cell Cycle 9 (23), 4622-4626",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9683891495628538697,8,2010
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer,"AC Fan, JJ O'Rourke, DR Praharaj, DW Felsher","Expert opinion on investigational drugs 22 (11), 1495-1509",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5895657566515058329,7,2013
O-GlcNAcylation is required for mutant ,"K Taparra, H Wang, R Malek, A Lafargue, MA Barbhuiya, X Wang, ...","The Journal of clinical investigation 128 (11), 4924-4937",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17779883241887784965,6,2019
Selective androgen receptor modulators in cancer cachexia?,KH Fearon,"The Lancet Oncology 14 (4), 271-272",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12786343846647403509,6,2013
Review Putting Oncogenes into a Developmental Context,DW Felsher,"Cancer biology & therapy 3 (10), 942-944",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11044916956257616419,6,2004
A novel octamer regulatory element in the VH11 leader exon of B-1 cells.,"L Goodglick, DW Felsher, MS Neshat, J Braun","The Journal of Immunology 154 (9), 4546-4556",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10850950026016045823,6,1995
A broad-spectrum integrative design for cancer prevention and therapy,"KI Block, C Gyllenhaal, L Lowe, A Amedei, ARMR Amin, A Amin, ...","Seminars in cancer biology 35 (Suppl), S276",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9760233801967781341,5,2015
Oncogene addiction: resetting the safety switch?,"Y Li, PS Choi, DW Felsher","Oncotarget 5 (18), 7986",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12138407708687539608,5,2014
The MYC oncogene cooperates with sterol-regulated element-binding protein to regulate lipogenesis essential for neoplastic growth,"AM Gouw, K Margulis, NS Liu, SJ Raman, A Mancuso, GG Toal, L Tong, ...","Cell metabolism 30 (3), 556-572. e5",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8653714610273888507,4,2019
Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin’s lymphoma treated with PEP-C,"CA To, RW Hsieh, JS McClellan, W Howard, NJ Fischbein, JMY Brown, ...","Case Reports 2012, bcr0820114578",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7018267649641157557,4,2012
MYC regulates the HIF2α stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells,"B Das, B Pal, R Bhuyan, H Li, A Sarma, S Gayan, J Talukdar, S Sandhya, ...","Cancer research 79 (16), 4015-4025",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12989374313048589063,3,2019
ARF: connecting senescence and innate immunity for clearance,"AY Kearney, B Anchang, S Plevritis, DW Felsher","Aging (Albany NY) 7 (9), 613",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8542837123365875839,3,2015
miR-17–92 explains ,"Y Li, SC Casey, PS Choi, DW Felsher","Molecular & cellular oncology 1 (4), e970092",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7876225157573834536,3,2014
Radiosensitization of MYC-overexpressing prostate cancer cells by statins.,"T Salih, K Aziz, S Thiyagarajan, M Armour, B Shanmugam, J Zeng, ...","Journal of Clinical Oncology 29 (7_suppl), 26-26",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=688951282086674559,3,2011
Identifying critical signaling molecules for the treatment of cancer,"C Arvanitis, PK Bendapudi, P Bachireddy, DW Felsher","Targeted Interference with Signal Transduction Events, 5-24",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3959170330980803982,3,2007
A Tale of Two Complications of Obesity: Nonalcoholic steatohepatitis (NASH) and Hepatocellular carcinoma (HCC),"R Dhanasekaran, DW Felsher",Hepatology,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17452637621062316155,2,2019
Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma,"I Lai, S Swaminathan, V Baylot, A Mosley, R Dhanasekaran, M Gabay, ...","Journal for immunotherapy of cancer 6 (1), 125",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9035807306890013485,2,2018
Correction: combined analysis of murine and human microarrays and chip analysis reveals genes associated with the ability of myc to maintain tumorigenesis,"CH Wu, D Sahoo, C Arvanitis, N Bradon, DL Dill, DW Felsher",PLoS genetics 9 (10),https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2930269439343147932,2,2013
A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi …,"AC Fan, L Xu, KJ Sridhar, M Tran, P Banerjee, JP Renschler, ...","Blood 118 (21), 3808-3808",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=6397343219403045873,2,2011
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910. Na,"M Seetharam, M Tran, AC Fan, L Xu, JP Renschler, DW Felsher, ...","Blood 116 (21), 4010-4010",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=5951740301035604077,2,2010
Discovery and validation of cancer biomarkers using a protein analysis methodology to analyze specimens,"DW Felsher, A Fan","US Patent App. 12/757,745",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15859119235615411877,2,2010
Nanoscale approaches to define biologic signatures and measure proteomic response to targeted therapies in hematologic and solid tumors,"AC Fan, JL Dermody, C Kong, N Zhang, L Xu, JP Renschler, MW Orban, ...","Clinical Cancer Research 16 (19 Supplement), PR6-PR6",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=12244281509352701887,2,2010
Abstract B178: Nanoscale quantification of phosphorylated and unphosphorylated ERK and MEK isoforms differentiates tumor and nontumor clinical specimens,"AC Fan, JL Dermody, C Kong, N Zhang, MW Orban, R Pai, L Xu, ...","Molecular Cancer Therapeutics 8 (12 Supplement), B178-B178",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=15026940410142370860,2,2009
The current STATe of biomarkers to predict the response to anti-angiogenic therapies,"PT Tran, DW Felsher","Cancer biology & therapy 7 (12), 2004-2006",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=11741618020762744048,2,2008
MYC is the master switch between tumor dormancy and relapse in Hepatocellular carcinoma (HCC),"R Dhanasekaran, V Baylot, A Mosley, D Felsher","HEPATOLOGY 66, 966A-966A",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=7868309936034549196,1,2017
"Intratumoral administration of the immunotherapeutic combination anti-ctla4, anti-cd137 and anti-ox40: comparison to systemic administration, peri-draining lymph node injection …","JPO Hebb, A Mosley, FV Catalan, P Ellmark, P Norlen, DW Felsher","Blood 128 (22), 4172-4172",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=2746584592122271457,1,2016
Stem cell altruism may serve as a novel drug resistance mechanism in oral cancer,"B Pal, R Bayat-Mokhtari, H Li, R Bhuyan, J Talukdar, S Sandhya, A Sarma, ...","Cancer Research 76 (14 Supplement), 251-251",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=9925383917959358879,1,2016
Affordable cancer medications are within reach but we need a different approach,"DW Felsher, L Lowe","J Clin Oncol 34, 2194-2195",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=4674241240331317523,1,2016
A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation,"CI Nwabugwu, K Rakhra, DW Felsher, DS Paik",2013 35th Annual International Conference of the IEEE Engineering in …,https://scholar.google.com/scholar?oi=bibs&hl=en&cites=17289872339253032996,1,2013
Nano-scale proteomic profiles of response to targeted therapy in patients with RCC.,"AC Fan, J Leppert, JE Liliental, L Xu, TJ Metzner, E Shroff, A Yaghi, ...","Cancer Research 73 (8 Supplement), 2283-2283",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=14301686343108055958,1,2013
Oncogenic c-and N-Myc disrupt circadian rhythm.,"BJ Altman, A Hsieh, A Gouw, A Venkataraman, B Li, D Bellovin, ...","Cancer Research 73 (8 Supplement), 4616-4616",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=13177014569702572341,1,2013
Nanoscale proteomic profiling to define diagnostic signatures and biomarkers of therapeutic activity in patients with RCC.,"AC Fan, J Leppert, JE Liliental, L Xu, AE Thong, C Yost, A Yaghi, ...","Journal of Clinical Oncology 31 (6_suppl), 432-432",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=1883973300285153047,1,2013
Generation of a Tetracycline Regulated Mouse Model of MYC-Induced T-Cell Acute Lymphoblastic Leukemia,"K Rakhra, DW Felsher","The Myc Gene, 221-235",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=8956717630362244378,1,2013
"Use of nano-immuno assay to generate rapid, quantitative nanoscale proteomic profiling of the hypoxia pathway in renal cell carcinoma clinical specimens.","AC Fan, P Banerjee, J Leppert, LC Harshman, C Sabatti, JD Brooks, ...","Journal of Clinical Oncology 30 (15_suppl), 10513-10513",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18020406543966067180,1,2012
Comparative genomic hybridization using mouse cDNA microarrays and its application to a murine lymphoma model,"L Bullinger, S Sander, A Karlsson, S Giuriato, T Hernandez-Boussard, ...","Cancer Research 64 (7 Supplement), 376-377",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=10070819268728119603,1,2004
Defining when inactivation of the MYC oncogene is sufficient to result in sustained regression of lymphoma.,DW Felsher,"Clinical immunology 103 (3), S144-S144",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=18009672495909982638,1,2002
c‐,"J Braun, DW Felsher, LA Goodglick","Annals of the New York Academy of Sciences 651 (1), 467-469",https://scholar.google.com/scholar?oi=bibs&hl=en&cites=3013873392884704096,1,1992
Mebendazole for Differentiation Therapy of Acute Myeloid Leukemia Identified by a Lineage Maturation Index,"Y Li, D Thomas, A Deutzmann, R Majeti, DW Felsher, DL Dill","Scientific reports 9 (1), 1-9",,0,2019
MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B-and T-Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling,"S Swaminathan, LD Heftdal, D Liefwalker, R Dhanasekaran, ...","Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …",,0,2019
Target genes in myc-driven neoplasia,"A Deutzmann, DW Felsher, Y Li","US Patent App. 16/468,656",,0,2019
Discovery and validation of cancer biomarkers using a protein analysis methodology to analyze specimens,"DW Felsher, A Fan","US Patent App. 16/180,385",,0,2019
CROSS-SPECIES COMPREHENSIVE PROTEOMIC ANALYSIS OF HEPATOCELLULAR CARCINOMA (HCC) TO IDENTIFY PLASMA BIOMARKERS OF VASCULAR INVASION,"M Krishnan, V Arjunan, N Kothary, D Felsher, R Dhanasekaran","HEPATOLOGY 70, 74A-74A",,0,2019
Analysis of response to therapeutics in cancer,"A Gouw, A Fan, DW Felsher","US Patent App. 16/356,582",,0,2019
Conditional Upregulation of IFN-α Alone Is Sufficient to Induce Systemic Lupus Erythematosus,"C Akiyama, K Tsumiyama, C Uchimura, E Honda, Y Miyazaki, K Sakurai, ...","The Journal of Immunology 203 (4), 835-843",,0,2019
Mistletoe extract Fraxini inhibits the proliferation of liver cancer by down-regulating c-Myc expression,"P Yang, Y Jiang, Y Pan, X Ding, P Rhea, J Ding, DH Hawke, D Felsher, ...","Scientific reports 9 (1), 6428",,0,2019
"Methods of identifying and treating immune checkpoint inhibitor-responsive neoplasms and cells, transgenic animals and kits for use therein","DW Felsher, SCC Parks","US Patent App. 16/080,980",,0,2019
Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis,"D Felsher, M Ryan, R Tibshirani","US Patent App. 15/758,544",,0,2019
MYC Functions As a Master Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies,"S Swaminathan, LD Heftdal, DF Liefwalker, R Dhanasekaran, ...","Blood 132 (Supplement 1), 2619-2619",,0,2018
"Myc-reporters, cells containing myc-reporters and methods of use thereof","A Deutzmann, DW Felsher, Y Li","US Patent App. 15/957,816",,0,2018
MYC-driven lymphomas suppress NK surveillance by blocking maturation of early NK cells,"LD Heftdal, S Swaminathan, DW Felsher","Cancer Research 78 (13 Supplement), 126-126",,0,2018
MYC Functions as a Switch for Natural Killer Cell-Mediated Immune Surveillance of Lymphoid Malignancies,"S Swaminathan, L Heftdal, D Liefwalker, R Dhanasekaran, A Deutzmann, ...","bioRxiv, 503086",,0,2018
Tumor‐Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons,"WH Bisson, A Amedei, L Memeo, S Forte, DW Felsher",Translational Toxicology and Therapeutics: Windows of Developmental …,,0,2017
MYC through HIF-2α regulates the altruistic stemness program in human leukemia stem cells,"B Pal, A Sarma, J Talukdar, S Bhuyan, S Sandhya, S Gayan, G Gogoi, ...","Clinical Cancer Research 23 (24 Supplement), 42-42",,0,2017
Abstract PR02: Synthetic lethality screen identifies novel druggable targets in the MYC pathway,"Y Li, A Deutzmann, J Bell, H Ji, D Felsher","Molecular Cancer Therapeutics 16 (10 Supplement), PR02-PR02",,0,2017
Metabolic aging by MYC: Distinct lipid accumulation and phospholipid suppression by MYC in lungs and kidneys detected by Desorption Electro Spray Ionization Mass Spectrometry …,"AM Gouw, K Margulis, RN Zare, DW Felsher","Experimental Gerontology 94, 117",,0,2017
Discovery and Validation of Cancer Biomarkers Using a Protein Analysis Methodology to Analyze Specimens,"DW Felsher, A Fan","US Patent App. 15/004,601",,0,2017
MYC functions as a master switch for natural killer cell-mediated immune surveillance of lymphoid malignancies,"S Swaminathan, A Mosley, C Horton, DF Liefwalker, A Deutzmann, ...","Cancer Research 77 (13 Supplement), 2943-2943",,0,2017
Inhibition of MYC-induced lipogenesis prevents renal cell carcinoma initiation and progression,"A Gouw, K Margulis, D Sullivan, G Toal, L Eberlin, C Dang, R Zare, ...",ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 253,,0,2017
Oncogenes and the Initiation and Maintenance of Tumorigenesis,"DW Felsher, C Arvanitis, P Bendapudi, P Bachireddy","The Molecular Basis of Human Cancer, 143-157",,0,2017
SNAI1 Regulates the Hexosamine Biosynthesis Pathway to Promote Kras Mutant Lung Tumorigenesis,"KT Taparra, H Wang, R Malek, K Nugent, J Groves, G Yildirir, B Simons, ...","International Journal of Radiation Oncology• Biology• Physics 96 (2), S54-S55",,0,2016
BIM-mediated apoptosis and oncogene addiction,"Y Li, A Deutzmann, DW Felsher","Aging (Albany NY) 8 (9), 1834",,0,2016
SNAI1 regulates the hexosamine biosynthetic pathway to promote tumorigenesis and oncogene-induced senescence escape in lung cancer,"K Taparra, H Wang, K Nugent, R Malek, J Groves, G Yildirir, B Simons, ...","Cancer Research 76 (14 Supplement), 1054-1054",,0,2016
The MYC oncogene regulates the immune response,DW Felsher,"INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 38, S83-S83",,0,2016
Abstract B2-12: A systems biology approach for the discovery of differentiation therapeutics,"Y Li, J Seita, D Felsher, DL Dill","Cancer Research 75 (22 Supplement 2), B2-12-B2-12",,0,2015
Abstract A2-35: Discovery of differentiation therapeutics using a systems biology approach,"Y Li, J Seita, D Felsher, D Dill","Cancer Research 75 (22 Supplement 1), A2-35-A2-35",,0,2015
Abstract PR13: miR-17-92 mediates MYC oncogene addiction,"Y Li, PS Choi, SC Casey, DL Dill, DW Felsher","Molecular Cancer Research 13 (10 Supplement), PR13-PR13",,0,2015
Abstract B02: The role of the immune system in sustained tumor regression following oncogene inactivation,"SC Casey, RK Do, DW Felsher","Molecular Cancer Research 13 (10 Supplement), B02-B02",,0,2015
Abstract A48: Gene expression signatures associated with MYC oncogene addiction in lymphoma,"D Koch, S Adams, A Gentles, B Anchang, D Sullivan, S Plevritis, ...","Molecular Cancer Research 13 (10 Supplement), A48-A48",,0,2015
Abstract IA12: Mechanisms of MYC addiction,D Felsher,"Molecular Cancer Research 13 (10 Supplement), IA12-IA12",,0,2015
Abstract PR14: HIF-2alpha regulates self-renewal of MYC dependent cancer stem cells,"B Das, H Li, R Bhuyan, DW Felsher","Molecular Cancer Research 13 (10 Supplement), PR14-PR14",,0,2015
The role of CD4 T cells in murine model of NASH-promoted HCC,"C Ma, D Felsher, T Greten","Cancer Research 75 (15 Supplement), 3166-3166",,0,2015
MYC and HIF-2alpha cooperates in oral squamous carcinoma cell self-renewal during hypoxia,"H Li, J Talukdar, S Sandhya, S Bhuyan, S Gayan, A Sarma, RB Mokhtari, ...","Cancer Research 75 (15 Supplement), 1529-1529",,0,2015
Snai1 accelerates Kras driven lung tumorigenesis by overcoming oncogene-induced senescence,"K Taparra, H Wang, K Nugent, R Williams, R Malek, J Cades, D Felsher, ...","Cancer Research 75 (15 Supplement), 2291-2291",,0,2015
Oncogene addiction and metabolism,DW Felsher,"INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 36, S7-S7",,0,2015
Leukemia Cell Differentiation upon Targeted Therapy Revealed By a Systems Biology Approach,"Y Li, J Seita, DW Felsher, D Dill","Blood 124 (21), 5202-5202",,0,2014
TM-06MYC AND MYCN DISRUPTION OF THE MOLECULAR CLOCK IN CANCER CELLS,"A Hsieh, B Altman, Z Stine, A Gouw, A Venkataraman, B Li, ...","Neuro-oncology 16 (Suppl 5), v214",,0,2014
MODELING AND PREDICTING CONSEQUENCES OF THERAPEUTIC ONCOGENE INACTIVATION,DW Felsher,"ANTICANCER RESEARCH 34 (10), 5903-5903",,0,2014
Oncogenic Myc disrupts NAMPT circadian oscillation in mouse hepatocellular carcinoma cell line,"AL Hsieh, BJ Altman, A Venkataraman, DI Bellovin, DW Felsher, ...","Cancer Research 74 (19 Supplement), 1419-1419",,0,2014
Rev-erbα modulates Myc-driven cancer cell growth and altered metabolism,"BJ Altman, A Hsieh, AM Gouw, ZE Stine, A Venkataraman, DI Bellovin, ...","Cancer Research 74 (19 Supplement), 2953-2953",,0,2014
Method of determining the prognosis of hepatocellular carcinomas using a multigene signature associated with metastasis,"DW Felsher, P Tran, S Adam, DI Bellovin","US Patent App. 14/131,925",,0,2014
Archive for the ‘Dehydrogenase’Category,A Lev-Ari,"CMAJ (Canadian Medical Association Journal) 9, 22",,0,2014
Twist1 Overexpression Induces Increased Tumor Cell Aggressiveness and Resistance to Sorafenib in Hepatocellular Carcinoma Cells,"A Wild, D Bellovin, ST Chettiar, N Gandhi, RP Gajula, RD Williams, ...","International Journal of Radiation Oncology• Biology• Physics 87 (2), S659",,0,2013
Tumor Response Prediction to Therapy,"PT Tran, P Bendapudi, HT Lin, DS Paik, DW Felsher","US Patent App. 13/680,090",,0,2013
[F-18] CAIP a smart PET tracer for imaging caspase-3 induced Apoptosis,"S Bin, J Jeon, M Palner, T Ling, D Felsher, SS Gambhir, FT Chin, ...","JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS 56, S6-S6",,0,2013
Abstract LB-313: Development of a novel anti-MYC therapeutic with efficacy against liver and kidney cancers.,"DI Bellovin, A Yevtodiyenko, SJ Adam, H Fernando, J Arzeno, M Gabay, ...","Cancer Research 73 (8 Supplement), LB-313-LB-313",,0,2013
603 NANO-SCALE PROTEOMIC PROFILING TO DEFINE DIAGNOSTIC SIGNATURES AND BIOMARKERS OF THERAPEUTIC ACTIVITY IN RCC,"J Leppert, A Fan, J Liliental, L Xu, A Thong, C Yost, A Yaghi, T Metzner, ...","The Journal of Urology 189 (4S), e246-e247",,0,2013
Human embryonic stem cells exhibit altruistic behavior in the microenvironment of oxidative stress,"B Das, R Tsuchida, R Bayat-Mokhtari, DW Felsher, H Yeger","Cytotherapy 15 (4), S6",,0,2013
Imaging the role of the immune system during oncogene-induced tumorigenesis,DW Felsher,"JOURNAL OF NUCLEAR MEDICINE 54, 31-31",,0,2013
Dissection of the role of the tumor microenvironment in oncogene addiction by ex vivo and in situ imaging,"L Tong, J Jeon, B Shen, R Jianghong, F Chin, S Gambhir, D Felsher","JOURNAL OF NUCLEAR MEDICINE 54, 25-25",,0,2013
In Vivo Imaging-Based Mathematical Modeling Techniques That Enhance the Understanding of Oncogene Addiction in relation to Tumor Growth,"C Nwabugwu, K Rakhra, D Felsher, D Paik",Computational and mathematical methods in medicine 2013,,0,2013
Mathematical modeling of the interactions between cellular programs in response to oncogene inactivation: Incorporation of both cell intrinsic and cell extrinsic (Immune …,"C Nwabugwu, K Rakhra, D Felsher, D Paik",2012 IEEE 12th International Conference on Bioinformatics & Bioengineering …,,0,2012
Nanoscale Proteomic Analysis of Oncoproteins in Hematopoietic Cancers,DW Felsher,STANFORD RESEARCH INST MENLO PARK CA,,0,2012
Transgenic mouse model of Twist1-induced metastasis reveals genes highly prognostic for human hepatocellular carcinoma,"DI Bellovin, PT Tran, SJ Adam, AJ Gentles, XW Wang, DW Felsher","Cancer Research 72 (8 Supplement), 2975-2975",,0,2012
Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer,"AC Fan, P Banerjee, L Xu, C Kong, C Sabatti, F Wilhelm, P Greenberg, ...","Cancer Research 72 (8 Supplement), 1280-1280",,0,2012
Abstract LB-429: Dormant cancer cells contribute to residual disease in a mouse model for reversible pancreatic cancer,"WC Lin, N Rajbhandari, C Liu, K Sakamoto, S Batra, R Opavsky, ...","Cancer Research 72 (8 Supplement), LB-429-LB-429",,0,2012
Abstract LB-443: The Simple Western rapidly generates quantitative profiles of MAPK and PI3K proteins in clinical specimens,"AC Fan, P Banerjee, DW Felsher","Cancer Research 72 (8 Supplement), LB-443-LB-443",,0,2012
Distinct roles of p53 and p19ARF in MYC-dependent tumor oncogene addiction,"SJ Adam, A Yetil, O Gevaert, V Jojic, A Gentles, DW Felsher","Cancer Research 72 (8 Supplement), 4879-4879",,0,2012
Cancer Stem Cells and Oncogene Addiction,DW Felsher,"CELLULAR ONCOLOGY 35, S8-S8",,0,2012
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect: Cryptococcal osteomyelitis and meningitis in a patient with non-hodgkin’s lymphoma …,"CA To, RW Hsieh, JS McClellan, W Howard, NJ Fischbein, JMY Brown, ...",BMJ Case Reports 2012,,0,2012
Survival and Death Signals Can Be Used to Predict when Oncogene Inactivation Will Elicit Oncogene Addiction,"PT Tran, PK Bendapudi, HJ Lin, P Choi, S Koh, J Chen, G Horng, ...","Science translational medicine 3 (103), 103ra99",,0,2011
A novel mouse model for the study of c-MYC during initiation and progression of pancreatic ductal adenocarcinoma,"WC Lin, Q Zhang, R Opavsky, DJ DiMaio, DW Felsher, SK Batra, ...","Cancer Research 71 (8 Supplement), 2384-2384",,0,2011
Regulation of nucleostemin by reactive oxygen species,"M Huang, P Whang, JV Chodaparambil, DA Pollyea, B Kusler, L Xu, ...","Cancer Research 71 (8 Supplement), 2069-2069",,0,2011
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis,"AC Fan, M Goldstein, GP Nolan, D Felsher",,,0,2011
Reversing oncogene-induced tumorigenesis,DW Felsher,"INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 28, S31-S31",,0,2011
ABT-737 Targets Leukemic Stem Cells In Mouse Models of Mutant NRASD12/hBCL-2-Mediated Acute Myeloid Leukemia Progression with Increased Survival,"RA Padua, S Beurlet, P Krief, N Omidvar, C Le Pogam, D Auboeuf, ...","Blood 116 (21), 3308-3308",,0,2010
miR-16 participates in tumor angiogenesis expressing X-ALK oncogene fusion,"E Dejean, MH Renalier, M Foisseau, X Agirre, GR De Paiva, T Al Saati, ...","BULLETIN DU CANCER 97, S22-S22",,0,2010
R15–Oral miR-16 participe à l’angiogenèse des tumeurs exprimant l’oncogène de fusion X-ALK,"E Dejean, MH Rénalier, M Foisseau, X Agirre, GR De Paiva, T Al Saati, ...","Bulletin du Cancer 97 (4), S22",,0,2010
Nano-immunoassay profiling of ERK and MEK isoforms in fine-needle aspirates of solid tumors.,"AC Fan, J Dermody, C Kong, N Zhang, AD Colevas, DW Felsher","Journal of Clinical Oncology 28 (15_suppl), 2564-2564",,0,2010
Identification of DKK2 as a candidate gene that facilitates tumor reoccurrence upon MYC inactivation,"SJ Adam, L Xu, A Karlsson, DW Felsher","Cancer Research 70 (8 Supplement), 5070-5070",,0,2010
NF-κB pathway inhibition delays the onset of MYC-induced liver cancer,"DI Bellovin, SJ Adam, Q Yang, DW Felsher","Cancer Research 70 (8 Supplement), 5036-5036",,0,2010
Development of a Micro-Computed Tomography–Based Image-Guided Conformal Radiotherapy System for Small Animals,"G Nelson, PT Tran, D Felsher, EE Graves",,,0,2010
Hypoxia in models of lung cancer: implications for targeted therapeutics Research output: Contribution to journal› Journal article› Research› peer-review,"EE Graves, M Vilalta, IK Cecic, JT Erler, PT Tran, D Felsher, L Sayles, ...",,,0,2010
Modeling and predicting oncogene addiction,DW Felsher,"INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 26, S31-S31",,0,2010
Development and characterization of conditional mouse models ob B-cells lymphoma ALK positive,"S Giuriato, M Foisseau, E Dejean, DW Felsher, T Al Saati, C Demur, ...","BULLETIN DU CANCER 96, S22-S22",,0,2009
"Development of a murine tumor model expressing the TPM3-ALK oncogene and luciferase. Use to validate imaging of bioluminiscence, the effectiveness of anti-ALK therapies","S Giuriato, N Faumont, E Bousquet, M Foisseau, A Bibonne, M Moreau, ...","BULLETIN DU CANCER 96, S22-S23",,0,2009
SU‐FF‐J‐162: In Vivo Biological Evaluation of Micro‐CT Based 3D Conformal Radiotherapy System,"G Nelson, M Rodriguez, H Zhou, A Lee, J Wu, P Tran, D Felsher, P Keall, ...","Medical Physics 36 (6Part8), 2514-2514",,0,2009
Nanoscale analysis of changes in signaling proteins in patients treated with single agent atorvastatin for low-grade or refractory NHL,"AC Fan, MW Orban, AE Shirer, R Rajwanshi, C Kong, Y Natkunam, ...","Journal of Clinical Oncology 27 (15_suppl), 11011-11011",,0,2009
Abstract# LB-63: Investigating the Requirement of NF-\# 954; B Pathway Activation in MYC-Induced Liver Cancer,"D Bellovin, Q Yang, D Felsher","Cancer Research 69 (9 Supplement), LB-63-LB-63",,0,2009
Conditional NPM-ALK and TPM3-ALK transgenic mice,"S Giuriato, D Felsher, A Saati, C Demur, A Ragab, A Kruczynski, C Schiff, ...","BULLETIN DU CANCER 95, S28-S28",,0,2008
MYC Potentiates DNA Damage Response Dependent Cellular Senescence,"PT Tran, J Chen, P Choi, G Horng, DW Felsher","International Journal of Radiation Oncology• Biology• Physics 72 (1), S693",,0,2008
Evaluation of targeted therapeutics in cell lines and patient samples by quantifying signal transduction and protein levels,"D Voehringer, D Deb-Basu, A Fan, D Felsher, E Haura","Clinical Cancer Research 14 (15 Supplement), A7-A7",,0,2008
Identification of proteomic changes in signaling upon oncogene inactivation after therapeutic treatment in hematopoietic tumors using a novel nanoscale-immunoassay system,D Felsher,"ANNALS OF ONCOLOGY 19, 200-200",,0,2008
Biological and clinical effects of single agent treatment with atorvastatin in patients with non-Hodgkin’s lymphoma,"AC Fan, M Orban, HE Lee, AE Shirer, R Rajwanshi, C Kong, Y Natkunam, ...","Journal of Clinical Oncology 26 (15_suppl), 8529-8529",,0,2008
DNA Vectorology: In Vivo Non-Viral Delivery,"LE Woodard, A Keravala, WE Jung, OL Wapinski, J Sage, DW Felsher, ...","Molecular Therapy 16, 1",,0,2008
The epigenetic context determines myc's oncogenic potential in a conditional mouse model for osteosarcoma,"J van Riggelen, D Felsher","Cancer Research 68 (9 Supplement), 64-64",,0,2008
Comparative analysis of murine and human microarrays reveals a gene signature associated with the ability of myc to maintain tumorigenesis,"CH Wu, D Sahoo, C Arvanitis, N Bradon, D Felsher","Cancer Research 68 (9 Supplement), 4941-4941",,0,2008
Monitoring changes in signaling proteins upon oncogene inactivation in hematopoietic tumors using a nano-immunoassay system,"A Fan, D Deb-Basu, J Gotlib, D Voehringer, D Felsher","Cancer Research 68 (9 Supplement), 3652-3652",,0,2008
Measurement of oncoproteins in primary hematopoietic malignancies pre-and post therapy using a nano-immunoassay system,"D Deb-Basu, A Fan, D Voehringer, D Felsher","Cancer Research 68 (9 Supplement), 5145-5145",,0,2008
Oncogene addiction-Response,DW Felsher,"CANCER RESEARCH 68 (9), 3080-3080",,0,2008
162. Oval Cell Expansion Through Wnt Signaling Shortens Tumor Latency During MYC Induced Hepatocarcinogenesis,"M Kurobe, M Hu, S Beer, S Ghole, YJ Jeong, D Felsher, KG Sylvester","Journal of Surgical Research 144 (2), 249",,0,2008
A nano-immunoassay system for monitoring targeted drug impact on signaling pathways from small samples of primary hematopoietic malignancies,"A Fan, W Lachnit, D Deb-Basu, D Voehringer, D Felsher","Clinical Cancer Research 13 (22 Supplement), C22-C22",,0,2007
Targeting HMGcoA reductase for prevention of MYC expressing lymphoma.,"C Shachaf, O Perez, S Elchuri, D Mitchell, D Felsher, G Nolan","Molecular Cancer Therapeutics 6 (11 Supplement), C181-C181",,0,2007
A nano-immunoassay system for monitoring changes in signaling upon oncogene inactivation in hematopoietic tumors,"A Fan, D Deb-Basu, J Gotlib, D Voehringer, D Felsher","Molecular Cancer Therapeutics 6 (11 Supplement), C259-C259",,0,2007
A novel nano-immunoassay system capable of absolute protein measurements from 400 tumor-derived stem cells,"D Voehringer, D Deb-Basu, I Weissman, A Fan, U Nguyen, A Bhamidipati, ...","Molecular Cancer Therapeutics 6 (11 Supplement), C92-C92",,0,2007
Predictive Modeling of Tumor Regression Kinetics Using a Murine Model of Oncogene-Addicted Lung Cancers,"PT Tran, J Lin, P Bendapudi, S Koh, K Komatsubara, G Horng, J Chen, ...","International Journal of Radiation Oncology• Biology• Physics 69 (3), S596-S597",,0,2007
Reversible tumorigenesis upon ALK oncogene inactivation,"S Guicato, T Al Saati, D Felsher, G Delsol, F Meggetto","BULLETIN DU CANCER 94, S289-S289",,0,2007
Identifying Critical Signaling Molecules for the Treatment of Cancer,"DW Felsher, C Arvanitis, PK Bendapudi, P Bachireddy","Targeted Interference with Signal Transduction Events 172, 2",,0,2007
Loss of ATM or H2AX accelerates MYC-induced tumorigenesis and prevents sustained tumor regression,"P Choi, K Rabin, S Giuriato, S Ray, Q Yang, D Felsher","Cancer Research 67 (9 Supplement), 5695-5695",,0,2007
Nano-fluidic detection of oncoprotein signaling in clinical samples,"A Fan, D Deb-Basu, A Shirer, M Horoschak, D Voehringer, R O'Neill, ...","Cancer Research 67 (9 Supplement), 2668-2668",,0,2007
Monitoring drug impact on signaling pathways from small samples of primary hematopoietic malignancies,"D Deb-Basu, A Fan, D Voehringer, R O'Neill, D Felsher","Cancer Research 67 (9 Supplement), 2826-2826",,0,2007
Cellular senescence programs are an important mechanism of tumor regression upon MYC inactivation,"CH Wu, J van Riggenlen, A Yetil, D Felsher","Cancer Research 67 (9 Supplement), 4505-4505",,0,2007
"C-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma (vol 20, pg 2096, 2006)","AP Weng, JM Millholland, Y Yashiro-Ohtani, ML Arcangeli, A Lau, C Wai, ...","GENES & DEVELOPMENT 21 (5), 625-625",,0,2007
ASPP2 Haploinsufficiency Promotes Tumor Formation in a Mouse Model.,"KM Kampa, JD Acoba, D Chen, K Beemer, J Gay, Z Zhu, E Padiernos, ...","Blood 108 (11), 4333-4333",,0,2006
Nano-Fluidic Detection of Oncoprotein Signaling in Preclinical and Patient Lymphoma Samples.,"AC Fan, D Deb-Basu, M Horoschak, A Shirer, D Voehringer, R O’Neill, ...","Blood 108 (11), 2527-2527",,0,2006
PMCID: PMC3446847.,"C Bianco, CG Rodriguez, H Sai, J Tobias, Y Li, MS Wolfe, C Shachaf, ...","apoptosis 5 (12), 1342-7",,0,2006
Nanoliter-scale Western-blot-like BCL-2 analysis of lymphoma fine needle aspirates,"AC Fan, D Voehringer, D Deb-Basu, J Gossett, O Roger, DW Felsher","Cancer Research 66 (8 Supplement), 591-591",,0,2006
"MYC or RAS, but not BCL2 expression induces reversible lymphomagenesis","AC Fan, S Giuriato, A Karlsson, P Bachireddy, P Bendapudi, K Rakhra, ...","Cancer Research 66 (8 Supplement), 62-62",,0,2006
"MYC quantification in lymphoma fine needle aspirates using “Firefly,” a novel nanofluidic protein analysis system","AC Fan, D Voehringer, D Deb-Basu, J Gossett, R O’Neill, D Felsher","Cancer Research 66 (8 Supplement), 852-852",,0,2006
"Two Oncogenic Hits Are Required To Initiate Lymphomagenesis in Adult, but Not Neonatal Hosts.","AC Fan, S Giuriato, A Karlsson, RA Padua, DW Felsher","Blood 106 (11), 2604-2604",,0,2005
FORMERLY MOLECULAR MEDICINE TODAY,"CM Shachaf, DW Felsher, T Okazaki, T Honjo, S Mocellin, M Lise, D Nitti, ...",,,0,2005
"Characterization of tumor dormancy and the liver cancer stem cell, uncovered upon MYC inactivation in hepatocellular cancer","CM Shachaf, PK Bendapudi, NJ Bradon, Q Yang, AD Borowsky, ...","Cancer Research 65 (9 Supplement), 481-481",,0,2005
Characterization of genomic lesions associated with escape from oncogene dependence.,"A Karlsson, L Bullinger, Y Kim, J Pollack, DW Felsher","Cancer Research 65 (9 Supplement), 33-33",,0,2005
The MYC oncogene and cancer: orchestrator out of control,"CM Shachaf, DW Felsher","Trends in Molecular Medicine 7 (11), 316-321",,0,2005
O-14 A reversible two-step model ofMDS/preleukemia: Transgenic mice expressing inducible BCL2 and mutant NRAS,"RA Padua, N Omidvar, S Kogan, TH Phan, R West, D Felsher, ...","Leukemia Research, S5",,0,2005
Cooperation between ,"AC Fan, S Giuriato, C Feng, RA Padua, D Felsher","Blood 104 (11), 1530-1530",,0,2004
Reversible tumorigenesis,DW Felsher,"Cancer Biology & Therapy 3 (10), 942-944",,0,2004
Differentiative context and gene expression by c-MYC,"CH Wu, N Bradon, M Lin, C Arvanitis, M Schaner, S Giuriato, PO Brown, ...","Cancer Research 64 (7 Supplement), 1281-1281",,0,2004
MYC inactivation induces tumor regression through the recovery of a functional DNA damage response,"K Rabin, S Giuriato, S Ray, DW Felsher","Cancer Research 64 (7 Supplement), 1281-1281",,0,2004
Developmental age defines the ability of MYC to induce cellular growth versus proliferation and tumorigenesis,"S Beer, A Zetterberg, RA Ihrie, Q Yang, N Bradon, C Arvanitis, L Attardi, ...","Cancer Research 64 (7 Supplement), 1280-1281",,0,2004
MYC-induced lymphomagenesis is dependent on the developmental context,"AC Fan, S Giuriato, C Feng, DW Felsher","Cancer Research 64 (7 Supplement), 1280-1280",,0,2004
Defining the genetic contexts when MYC inactivation induces sustained regression of hematopoietic tumors.,"S Giuriato, E Passegue, A Fan, F Tang, DW Felsher","BLOOD 102 (11), 586A-586A",,0,2003
RAS and BCL-2 co-operate in a mouse model of myelodysplasia (MDS).,"RA Padua, C Chomienne, S Kogan, TH Phan, M Robledo, S Muszlak, ...","BLOOD 102 (11), 145A-145A",,0,2003
Restoration of p27 function prevents MYC from inducing genomic instability and apoptosis,"DW Felsher, D Deb-Basu, A Karlsson","MOLECULAR BIOLOGY OF THE CELL 13, 146A-146A",,0,2002
Threshold levels of MYC expression required to maintain a neoplastic phenotype is modulated by cell cycle regulatory genes.,"C Shachaf, D Deb-Basu, DW Felsher","CLINICAL IMMUNOLOGY 103 (3), S88-S89",,0,2002
Definining when MYC-induced lymphomagenesis is reversible.,"DW Felsher, F Tang, C Sundberg, A Karlsson, S Giuriato","BLOOD 98 (11), 97A-97A",,0,2001
"Myc inactivation in hematopoietic tumors that have lost p53 still regress, but subsequently relapse.","DW Felsher, F Tang, SS Song, S Beer","BLOOD 96 (11), 701A-701A",,0,2000
Hematopoietic tumorigenesis by MYC using a conditional transgenic model system.,"DW Felsher, JM Bishop","BLOOD 94 (10), 60A-60A",,0,1999
B-CELL-SPECIFIC DNA-BINDING TO THE VH11 LEADER SEQUENCE,"L GOODGLICK, D FELSHER, M ANDERSON, T HASSETT, J BRAUN","FASEB JOURNAL 5 (6), A1718-A1718",,0,1991
A murine model for the pathophysiology of CD5+ B-cells,DW Felsher,UCLA,,0,1991
HIF-2a Suppresses p53 to Enhance the Stemness and Regenerative Potential of Human Embryonic Stem Cells,"B DAS, R BAYAT-MOKHTARI, M TSUI, S LOTFI, R TSUCHIDA, ...",,,0,0
Posts Tagged ‘Immunotherapy’,D Felsher,"Receptor 7, 1",,0,0
Cryptococcal Osteomyelitis and Meningitis in a Non-Hodgkin's Lymphoma Patient Treated with PEP-C,"CA To, RW Hsieh, JS McClellan, W Howard, N Fischbein, JMY Brown, ...",BMJ case reports 2012,,0,0
693. Adverse shRNA Cytotoxicity Can Accelerate Tumorigenesis in Genetically Predisposed Mice,"MA Kay, D Felsher",,,0,0
2716 Predictive Modeling of Tumor Regression Kinetics using aMurine Model Of Oncogene-addicted Lung Cancers,"PT Tran, J Lin, P Bendapudi, S Koh, K Komatsubara, G Horng, J Chen, ...",,,0,0
Posts Tagged ‘oncogene’,D Felsher,"Receptor 7, 1",,0,0
Posts Tagged ‘mouse models’,D Felsher,"Receptor 7, 1",,0,0
Supplemental Data HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo,"P Gao, H Zhang, R Dinavahi, F Li, Y Xiang, V Raman, ZM Bhujwalla, ...",,,0,0
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse,"A Whetton, M Pla, R West, P Fenaux, C Chomienne, RA Padua, ...",,,0,0
